CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced
CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014
CN Bio Innovations’ (CN Bio) Investigator Meeting entitled “Hepatitis B: New models pave the way to a cure” was held on Monday 10th November 2014 at
NIH Director highlights LiverChip in Compton Lecture
Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on
TSB Funds New Research by CN Bio into Fatty Liver Disease
CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development
Imperial College London to present first public HBV data from CN Bio in vitro liver model
CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has
CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London
Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations
Promotion of Dr David Hughes to the role of Chief Technology Officer
Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for
CN Bio appoints Professor Mark Thursz as Scientific Advisor
CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable
CN Bio hires Director of Licensing
CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to